Sign in →

TEST ID LID Lidocaine, Serum

Reporting Name

Lidocaine, S

Specimen Type

Serum Red


Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube: Red top (serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Refrigerated (preferred) 14 days
  Ambient  14 days
  Frozen  14 days

Method Name

Enzyme-Multiplied Immunoassay Technique (EMIT)

Reject Due To

Gross hemolysis Reject

Reference Values

Therapeutic: 1.5-5.0 mcg/mL

Critical value: >6.0 mcg/mL

Day(s) Performed

Monday through Saturday

Report Available

Same day/1 to 2 days

Specimen Retention Time

2 weeks

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

80176

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Cardiovascular Test Request (T724)

-Therapeutics Test Request (T831)

Useful For

Assessing optimal lidocaine dosing during the acute management of ventricular arrhythmias following myocardial infarction or during cardiac manipulation such as surgery

 

Assessing potential lidocaine toxicity

Clinical Information

Lidocaine is commonly used as a local anesthetic, but it is also effective at controlling ventricular arrhythmia and ventricular fibrillation in children and adults. For cardiac therapy, optimal therapeutic response is seen when serum concentrations are between 1.5 and 5.0 mcg/mL. Lidocaine is protein-bound (60-80%), primarily to alpha-1-acid glycoprotein; concentrations of this protein increase after myocardial infarction, which may decrease the amount of free lidocaine and, thus, its efficacy.

 

Lidocaine undergoes extensive first-pass hepatic metabolism and, therefore, is not administered orally. It is eliminated via renal clearance, with a half-life of approximately 1.5 to 2 hours. Diseases that reduce hepatic or renal function reduce clearance and prolong elimination of lidocaine.

 

Toxicity occurs when the serum concentration of lidocaine is greater than 6.0 mcg/mL and is usually associated with symptoms of central nervous system excitation, light-headedness, confusion, dizziness, tinnitus, and blurred or double vision. This can be accompanied by bradycardia and hypotension leading to cardiovascular collapse.